# Oman Medical Devices Market Size, Share & Forecast, By Product Type, Care Setting & End User, 2025-2032 --- ## Market Overview # CHAPTER 1 - Market Overview The Oman Medical Devices Market is driven by recurring institutional procurement, replacement cycles and treatment volumes across hospitals, laboratories and ambulatory settings. Oman records more than **6,500 new diabetes cases annually**, more than **2,000 new cancer cases**, hypertension in approximately one-third of individuals and overweight or obesity in **66% of the population**, supporting durable diagnostic and therapeutic device utilization. Muscat is the principal high-acuity equipment and specialist-care hub because national referral hospitals, private tertiary facilities and distributor headquarters are concentrated around the capital. Oman International Hospital in Muscat spans approximately **42,000 square meters** and operates advanced imaging and clinical technology under a long-term technology partnership, reinforcing Muscat's role in premium equipment deployment, service contracts and clinical training. Regulatory access is increasingly formalized through the Ministry of Health Drug Safety Center. Standard medical-device registration carries a published service completion period of **60 working days**, while manufacturer registration is also structured around a 60-working-day process. This raises the importance of local representation, technical documentation, manufacturer licensing and post-market compliance when OEMs prioritize product launches and distributor portfolios. Oman remains structurally import dependent, but trade economics are changing. The India-Oman Comprehensive Economic Partnership Agreement entered into force on **1 June 2026** and provides India duty-free access across **98.08% of Oman's tariff lines**, covering 99.38% of Indian export value. The resulting landed-cost pressure should intensify competition among imported devices, consumables and component suppliers. ## KPIs at a Glance * Market Value: USD 566 million (2025) * Dominant Region: Muscat Governorate * Dominant Segment: Digital & Connected Devices (fastest growing) * Total Number of Players: 120 ## Future Outlook The Oman Medical Devices Market is projected to move from USD 566 million in 2025 to USD 857 million in 2031 and USD 921 million in 2032. The historical 2020-2025 CAGR of 7.73% reflected post-pandemic equipment normalization, hospital modernization and greater diagnostic intensity. The 2025-2032 forecast CAGR of 7.20% assumes continued public hospital commissioning, expansion of private treatment capacity and progressive replacement of conventional devices with higher-value digital, minimally invasive and point-of-care platforms. Growth is expected to remain value-led as technology mix and service content increase faster than physical device volumes. Forecast expansion is supported by a visible hospital pipeline and a tighter regulatory framework that improves supplier accountability. At the end of 2023, the Ministry of Health reported **50 hospitals with more than 5,000 beds** and nine additional hospitals under establishment. New facilities such as the 170-bed Samail Hospital broaden the installed base for imaging, laboratory, surgical, monitoring and critical-care systems. The market's principal profit-pool shift is expected toward connected equipment, consumable-linked platforms, maintenance contracts and recurring diagnostics rather than one-off capital equipment alone. --- | | | | --- | --- | | **7.20%** Forecast CAGR (2025-2032) | **$921 Mn** 2032 Projection | --- | | | | | | --- | --- | --- | --- | | Base Year **2025** | Historical Period **2020-2025** | Forecast Period **2025-2032** | Historical CAGR **7.73%** | --- ## Scope of the Report # CHAPTER 2 - Scope of the Market * **Geographic Coverage:** Sultanate of Oman * **Historical Period:** 2020-2025 * **Base Year:** 2025 * **Forecast Period:** 2025-2032 (base year inclusive) * **Market Segments Covered:** 7 primary segmentation dimensions (Product Type, Care Setting, End User, Disease Area, Channel, Technology, Geography) * **Companies Covered:** Top 10 key players profiled * **Currency & Units:** USD, values expressed in USD Mn/Bn ### Segmentation Data Tree * Product Type + Diagnostic Imaging - Computed Tomography & MRI - X-Ray & Ultrasound + In Vitro Diagnostics - Clinical Chemistry & Immunoassay - Molecular & Point-of-Care Diagnostics + Cardiovascular Devices - Cardiac Rhythm Management - Interventional Cardiology + Orthopedic & Implantable Devices - Joint Reconstruction - Trauma & Spine Implants * Care Setting + Public Hospitals - Tertiary Referral Hospitals - Regional General Hospitals + Private Hospitals - Multispecialty Hospitals - Specialist Hospitals + Specialty Clinics - Cardiology & Surgical Clinics - Diabetes & Chronic Care Clinics + Diagnostic Laboratories - Hospital Laboratories - Independent Laboratory Networks * End User + Ministry of Health Providers - Central Referral Facilities - Governorate Health Facilities + Other Government Providers - Military Healthcare Facilities - University & Public Institutional Hospitals + Private Hospital Groups - Large Multispecialty Groups - Independent Private Hospitals + Diagnostic Networks - Independent Laboratories - Imaging & Diagnostic Centers * Disease Area + Cardiovascular & Stroke - Cardiac Diagnostics - Interventional & Rhythm Management + Diabetes & Metabolic - Glucose Monitoring - Metabolic Diagnostics + Oncology - Cancer Diagnostics - Image-Guided & Therapeutic Devices + Orthopedics & Trauma - Joint Reconstruction - Trauma Fixation * Channel + Public Tenders - Central Procurement - Hospital Project Procurement + Direct Institutional Sales - OEM Direct Contracts - Enterprise Account Agreements + Authorized Distributors - National Device Distributors - Specialist Clinical Distributors + Private Group Procurement - Hospital Group Contracts - Diagnostic Network Contracts * Technology + Conventional Electromechanical - Standalone Diagnostic Equipment - Conventional Therapeutic Equipment + Digital & Connected Devices - Networked Monitoring Systems - Connected Diagnostic Platforms + AI-Enabled Diagnostics - AI Imaging Support - Algorithm-Assisted Clinical Decision Systems + Minimally Invasive Platforms - Image-Guided Intervention - Endoscopic & Catheter Platforms * Geography + Muscat Governorate - Central Muscat Healthcare Cluster - Greater Muscat Private Hospital Cluster + Al Batinah North & South - Sohar Healthcare Cluster - Rustaq & Coastal Facilities + Dhofar Governorate - Salalah Healthcare Cluster - Peripheral Dhofar Facilities + Interior, Sharqiyah & Border Governorates - Nizwa & Interior Cluster - Sharqiyah & Border Facilities --- ## Market Trajectory # Oman Medical Devices Market Size, Share & Forecast, By Product Type, Care Setting & End User, 2025-2032 **Geography:** Oman | **Study Period:** 2020-2032 | **Base Year:** 2025 | **Forecast Period:** 2025-2032 The Oman Medical Devices Market is estimated at **USD 566 million in 2025**, supported by hospital capacity additions, chronic-disease diagnostics, private healthcare investment and replacement of installed clinical equipment. More than **6,500 new diabetes cases are recorded annually**, sustaining demand for diagnostics, monitoring, laboratory systems and connected care devices. ## Report Metadata Summary | | | | --- | --- | | **Base Year** | 2025 | | **CAGR for Past 5 Years** | 7.73% | | **Historical Period** | 2020-2025 | | **Forecast Period** | 2025-2032 | | **Forecast Period CAGR** | 7.20% | # CHAPTER 3 - Market Size, Growth Forecast and Trends This section evaluates the historical market size, analyzes year-over-year growth dynamics, and presents forecast projections supported by market performance indicators and demand-side drivers. ### Historical and Projected Market Size (USD Mn) | Year | Market Size (USD Mn) | Period | | --- | --- | --- | | 2020 | 390 | Historical | | 2021 | 426 | Historical | | 2022 | 465 | Historical | | 2023 | 497 | Historical | | 2024 | 532 | Historical | | 2025 | 566 | Base Year | | 2026F | 606 | Forecast | | 2027F | 649 | Forecast | | 2028F | 695 | Forecast | | 2029F | 745 | Forecast | | 2030F | 799 | Forecast | | 2031F | 857 | Forecast | | 2032F | 921 | Forecast | ### YoY Growth Rate (%) | Year | YoY Growth (%) | | --- | --- | | 2021 | 9.2% | | 2022 | 9.2% | | 2023 | 6.9% | | 2024 | 7.0% | | 2025 | 6.4% | | 2026F | 7.1% | | 2027F | 7.1% | | 2028F | 7.1% | | 2029F | 7.2% | | 2030F | 7.2% | | 2031F | 7.3% | | 2032F | 7.5% | ### Market Value vs Volume Growth (%) | Year | Value Growth (%) | Volume Growth (%) | Mix / ASP Effect | | --- | --- | --- | --- | | 2020 | - | - | Base | | 2021 | 9.2% | 8.7% | +0.5 ppt | | 2022 | 9.2% | 8.5% | +0.7 ppt | | 2023 | 6.9% | 6.2% | +0.7 ppt | | 2024 | 7.0% | 6.1% | +0.9 ppt | | 2025 | 6.4% | 5.7% | +0.7 ppt | | 2026 | 7.1% | 6.2% | +0.9 ppt | | 2027 | 7.1% | 6.1% | +1.0 ppt | | 2028 | 7.1% | 6.0% | +1.1 ppt | | 2029 | 7.2% | 6.0% | +1.2 ppt | | 2030 | 7.2% | 5.9% | +1.3 ppt | | 2031 | 7.3% | 5.9% | +1.4 ppt | | 2032 | 7.5% | 6.0% | +1.5 ppt | ### Historical Market Performance (2020-2025) Historical performance accelerated during 2021-2022 as deferred equipment replacement, diagnostic capacity requirements and healthcare infrastructure investment supported annual growth of about 9.2%. Growth normalized to 6.9% in 2023 and 7.0% in 2024 as emergency procurement gave way to planned capital cycles. By end-2023, the Ministry of Health operated 265 healthcare institutions, including 50 hospitals with more than 5,000 beds, creating a sizable installed base requiring maintenance, upgrades, consumables and recurring diagnostic inputs. ### Forecast Market Outlook (2025-2032) The 2025-2032 trajectory implies a 7.20% CAGR, with annual value growth gradually increasing from 7.1% in 2026 to 7.5% by 2032. Growth is expected to become progressively mix-driven as connected monitoring, high-acuity imaging, minimally invasive intervention and point-of-care diagnostics command higher value per installation. Nine public hospitals reported under establishment at end-2023 provide a visible equipment pipeline, while tighter device registration and establishment-clearance rules favor suppliers with stronger regulatory, service and inventory capabilities. --- ## Market Breakdown # CHAPTER 4 - Market Breakdown The Oman Medical Devices Market is transitioning from episodic equipment procurement toward recurring platform, consumables and lifecycle-service economics. Investors should therefore track import exposure, institutional buying concentration and the rate at which connected equipment captures a larger share of clinical-device spending. | Year | Market Size (USD Mn) | YoY Growth (%) | Device Import Dependence (%) | Hospital Procurement Share (%) | Connected Device Revenue Share (%) | Period | | --- | --- | --- | --- | --- | --- | --- | | 2020 | 390 | - | 90% | 71% | 8% | Historical | | 2021 | 426 | 9.2% | 89% | 71% | 9% | Historical | | 2022 | 465 | 9.2% | 89% | 70% | 10% | Historical | | 2023 | 497 | 6.9% | 88% | 70% | 12% | Historical | | 2024 | 532 | 7.0% | 87% | 69% | 14% | Historical | | 2025 | 566 | 6.4% | 86% | 68% | 16% | Base Year | | 2026 | 606 | 7.1% | 86% | 68% | 18% | Forecast and Latest Operating KPIs | | 2027 | 649 | 7.1% | 85% | 67% | 20% | Forecast and Industry Outlook | | 2028 | 695 | 7.1% | 84% | 67% | 22% | Forecast and Industry Outlook | | 2029 | 745 | 7.2% | 83% | 66% | 24% | Forecast and Industry Outlook | | 2030 | 799 | 7.2% | 82% | 66% | 26% | Forecast and Industry Outlook | | 2031 | 857 | 7.3% | 81% | 65% | 28% | Forecast and Industry Outlook | | 2032 | 921 | 7.5% | 80% | 65% | 30% | Forecast and Industry Outlook | **KPI 1, Device Import Dependence:** **86% (2025, Oman model)**. Import exposure remains the core supply-chain risk and distributor value driver. Oman imported approximately **USD 80.3 million of HS 9018 medical instruments in 2024** before accounting for imaging, implants, IVD and other device categories. **KPI 2, Hospital Procurement Share:** **68% (2025, Oman model)**. Institutional buyers remain the primary profit pool because advanced equipment is concentrated in hospitals. The Ministry of Health reported **50 hospitals and more than 5,000 beds at end-2023**, alongside nine hospitals under establishment. **KPI 3, Connected Device Revenue Share:** **16% (2025, Oman model)**. Connected equipment is increasing service, software and lifecycle revenue per installed device. Oman International Hospital's approximately **42,000-square-meter Muscat facility** illustrates the shift toward advanced integrated clinical technology and long-term technology partnerships. --- --- ## Market Segmentation # CHAPTER 5 - Market Segmentation Framework Comprehensive analysis across key dimensions providing insights into market structure, consumer preferences, and distribution patterns. | | | | | --- | --- | --- | | **No of Segments:** 7 | **Dominant Segment:** Product Type | **Fastest Growing Segment:** Technology | ### Segmentation Framework | Priority | Level-1 Segment / Taxonomy Dimension | Level-2 Sub-Segments | | --- | --- | --- | | 1 | Product Type | Diagnostic Imaging; In Vitro Diagnostics; Cardiovascular Devices; Orthopedic & Implantable Devices; General & Surgical Devices | | 2 | Care Setting | Public Hospitals; Private Hospitals; Specialty Clinics; Diagnostic Laboratories; Home Healthcare | | 3 | End User | Ministry of Health Providers; Other Government Providers; Private Hospital Groups; Diagnostic Networks; Individual Patients | | 4 | Disease Area | Cardiovascular & Stroke; Diabetes & Metabolic; Oncology; Orthopedics & Trauma; Renal & Critical Care | | 5 | Channel | Public Tenders; Direct Institutional Sales; Authorized Distributors; Private Group Procurement; Retail & E-Commerce | | 6 | Technology | Conventional Electromechanical; Digital & Connected Devices; AI-Enabled Diagnostics; Minimally Invasive Platforms; Point-of-Care Devices | | 7 | Geography | Muscat Governorate; Al Batinah North & South; Dhofar Governorate; Interior, Sharqiyah & Border Governorates | ### Key Segmentation Takeaways Comprehensive analysis across all extracted segmentation dimensions providing insights into market structure, consumer preferences, and distribution patterns. **Product Type** - Product architecture remains the principal revenue-allocation lens because procurement budgets distinguish capital imaging systems, laboratory platforms, implantable devices and recurring surgical supplies. Diagnostic Imaging remains strategically important due to high ticket values, long replacement cycles and downstream maintenance revenue, while In Vitro Diagnostics creates more recurring reagent and consumable economics for suppliers. **Technology** - Technology is the fastest-changing dimension as healthcare providers migrate from standalone equipment toward connected monitoring, digital imaging, point-of-care diagnostics and minimally invasive workflows. Digital & Connected Devices are expected to lead incremental revenue growth because interoperability, remote monitoring and lifecycle service contracts allow OEMs to increase recurring revenue while hospitals improve asset utilization and clinical workflow visibility. --- ## Regional Analysis # CHAPTER 6 - Regional Analysis Oman ranks fifth by modeled 2025 medical-device market value among the six GCC economies, behind Saudi Arabia, UAE, Kuwait and Qatar but ahead of Bahrain. Its smaller absolute demand base is offset by hospital investment, formalizing regulation and an import-led supplier structure that can support above-peer growth. ### KPI Summary * Peer Country Ranking: **5th** * Oman Market Size: **USD 566 Mn** * Oman CAGR (2025-2032): **7.20%** | Country | Market Size | CAGR (%) | Health Expenditure per Capita (USD, latest available) | Medical-Device Import Dependence (%) | | --- | --- | --- | --- | --- | | Saudi Arabia | USD 6,380 Mn | 5.1% | 1,825 | 90% | | UAE | USD 3,180 Mn | 5.8% | - | 88% | | Kuwait | USD 813 Mn | 6.2% | - | 91% | | Qatar | USD 740 Mn | 6.0% | 1,804 | 90% | | Oman | USD 566 Mn | 7.2% | 732 | 86% | | Bahrain | USD 400 Mn | 5.5% | - | 85% | ### Market Position Oman ranks **5th among GCC peers** by modeled 2025 value, while Saudi Arabia alone reaches approximately **USD 6.38 billion**, highlighting Oman's smaller but strategically accessible procurement pool. ### Growth Advantage Oman's **7.20% forecast CAGR** exceeds UAE's reported **5.8%** and Saudi Arabia's **5.1%**, positioning Oman as a faster-growth GCC challenger despite its smaller installed base. ### Competitive Strengths Oman combines a **60-working-day device registration framework**, expanding hospital capacity and CEPA tariff liberalization across **98.08% of tariff lines**, improving route-to-market economics for compliant suppliers. Comprehensive analysis of key factors shaping the market, including growth catalysts, operational challenges, and emerging opportunities across production, distribution, and consumer segments. --- ## Growth Drivers # CHAPTER 7 - Growth Drivers, Challenges & Opportunities Comprehensive analysis of key factors shaping the Oman Medical Devices Market, including growth catalysts, operational challenges, and emerging opportunities across production, distribution, and consumer segments. ## Growth Drivers ### Expansion of Hospital Infrastructure and Installed Clinical Capacity Hospital expansion creates recurring demand for imaging, surgical, laboratory and monitoring systems, with **9 hospitals under establishment (2023, Oman)**. * Existing public infrastructure included **50 hospitals and more than 5,000 beds (2023, Oman)**, creating replacement, maintenance and consumables demand alongside greenfield procurement. * Samail Hospital adds **170 beds (project specification, Oman)**, supporting new demand for operating-room, critical-care, sterilization, imaging and bedside-monitoring systems. * Al Falah Hospital is designed with **170 beds and 38 outpatient clinics (project specification, Oman)**, widening addressable procurement for OEMs and service providers in South Al Sharqiyah. ### Rising Chronic Disease Diagnostic and Monitoring Intensity Chronic disease expands device utilization as Oman records more than **6,500 new diabetes cases annually (2025, Oman)**. * More than **2,000 new cancer cases annually (2025, Oman)** reinforce demand for imaging, pathology, biopsy, infusion-support and image-guided intervention technologies. * Approximately **one in three individuals has high blood pressure (2025, Oman)**, supporting recurring blood-pressure monitoring, cardiovascular diagnostics and chronic-care device demand. * Overweight or obesity affects **66% of the population (2025, Oman)**, increasing long-term diagnostic intensity and expanding the addressable installed base for metabolic and cardiovascular monitoring technologies. ### Private Healthcare Expansion and Quality Formalization Private capacity broadens addressable procurement, with approvals issued for **16 private hospitals in the referenced approval cycle (2024, Oman)**. * Initial approvals also covered **215 private health institutions (referenced 2024 cycle, Oman)**, increasing the number of potential diagnostic, monitoring and treatment-device buyers. * Private healthcare serves approximately **2 million expatriate beneficiaries (2024, Oman)**, giving private operators a large recurring patient base for diagnostics and specialist procedures. * Approximately **37 private health institutions participated in the Aman patient-safety initiative (2024, Oman)**, increasing emphasis on device quality, traceability and clinical-risk controls. --- ## Market Challenges ### High Dependence on Imported Devices and Components Supply continuity remains exposed to external2> ### High Dependence on Imported Devices and manufacturers, with **USD 80.3 million of HS 9018 imports (2024, Oman)** alone. * The HS 9018 category excludes several major device pools, meaning **USD 80.3 million (2024, Oman)** represents only part of total import exposure and understates broader dependency. * HS 9018 imports were around **USD 89 million in 2022 (Oman)** before declining in 2023, illustrating year-to-year volatility that can affect distributor inventory and working capital. * Import-led distribution requires local inventory resilience because government medical-supply operations serve a national network including regional warehouses in Nizwa and Salalah, increasing fulfillment complexity outside Muscat. ### More Formal Regulatory and Market-Access Requirements Commercial launches require greater planning because medical-device registration carries a published **60-working-day completion period (2025, Oman)**. * Manufacturer registration also requires approximately **60 working days (2025, Oman)**, making regulatory sequencing material to distributor appointment, launch timing and tender eligibility. * Oman's Drug Safety Center maintained dedicated medical-device circulars across **2025 and 2026**, indicating increasingly active post-market, establishment and registration oversight. * A **2026 circular** linked medical-device establishment approval with clearance services, increasing the operational cost of weak local compliance and favoring established channel partners. ### Small National Scale and Concentrated High-Acuity Demand Oman's monetizable device base is smaller than major GCC peers, while health spending was approximately **USD 732 per capita (2023, Oman)**. * Qatar's health expenditure was approximately **USD 1,804 per capita (2023, Qatar)**, illustrating the higher spending intensity available to device suppliers in some neighboring GCC markets. * Saudi Arabia's health expenditure was approximately **USD 1,825 per capita (2023, Saudi Arabia)**, reinforcing the scale disadvantage faced by suppliers pursuing Oman-only commercial models. * Oman's public system included **50 Ministry of Health hospitals at end-2023**, concentrating major capital-equipment opportunities into a relatively finite institutional-account universe. --- ## Market Opportunities ### CEPA-Enabled Sourcing and Supplier Portfolio Reconfiguration India-Oman CEPA improves sourcing economics through duty-free access across **98.08% of tariff lines (2026, Oman)**. * The agreement covers **99.38% of Indian export value (2026, India-Oman)**, creating a monetizable opportunity for distributors to add cost-competitive devices, components and consumables to Oman portfolios. * CEPA entered into force on **1 June 2026**, giving OEMs and distributors a defined timetable for repricing sourcing strategies and tender bids. * Bilateral trade reached **USD 11.18 billion in FY2025-26**, supporting logistics density and commercial connectivity that medical-device suppliers can leverage for faster regional replenishment. ### Connected Equipment and Lifecycle-Service Revenue Integrated technology models are gaining relevance, illustrated by a **10-year technology partnership in Muscat** around Oman International Hospital. * Oman International Hospital occupies approximately **42,000 square meters**, providing a reference environment for monetizing imaging, digital workflow, clinical engineering and lifecycle support. * The partnership structure spans **10 years**, demonstrating how suppliers can shift from one-time equipment sales toward recurring service, training and technology-upgrade revenue. * Oman's quality-assurance framework added a national clinical-risk guideline in **March 2025**, strengthening the business case for connected asset monitoring, preventive maintenance and traceable device performance. ### Local Technical Service, Warehousing and Regulatory Support Hubs Localization can capture recurring aftermarket value because device and manufacturer registration each have **60-working-day service frameworks (2025, Oman)**. * Oman's Directorate General of Medical Supplies operates regional warehousing infrastructure in locations including **Nizwa and Salalah**, showing the strategic importance of distributed inventory and service coverage. * Government supply operations cover **surgical and laboratory items** across Ministry of Health institutions, creating recurring opportunities in quality-assured consumables, stock management and technical support. * A **2026 establishment-clearance linkage** raises the value of locally capable regulatory and distribution partners that can manage product approval, clearance, inventory and field-service requirements together. --- --- ## Competitive Landscape # CHAPTER 8 - Competitive Landscape Overview The Oman Medical Devices Market is import-led and moderately concentrated at the advanced-equipment level, while distribution, consumables and biomedical service activities remain fragmented. Entry barriers center on regulatory registration, institutional tender access, clinical support, installed-base servicing and distributor quality. * **Key players:** 10 * **New Entrants (last 5 yrs):** - ### Company Profiles (Top 10 Players) | Company Name | Market Share | Headquarters | Founding Year | Core Market Focus | | --- | --- | --- | --- | --- | | Siemens Healthineers | - | Erlangen, Germany | 2017 | Diagnostic imaging, laboratory diagnostics, image-guided therapy and digital clinical systems | | GE HealthCare | - | Chicago, United States | 2023 | Imaging, ultrasound, patient monitoring and interventional systems | | Philips | - | Amsterdam, Netherlands | 1891 | Diagnostic imaging, patient monitoring, ultrasound and connected care | | Roche Diagnostics | - | Basel, Switzerland | 1896 | Clinical chemistry, immunoassay, molecular diagnostics and laboratory automation | | Abbott | - | Abbott Park, United States | 1888 | Point-of-care diagnostics, diabetes care, cardiovascular and diagnostic platforms | | Medtronic | - | Galway, Ireland | 1949 | Cardiovascular, surgical, neurological and minimally invasive devices | | Johnson & Johnson MedTech | - | New Brunswick, United States | 1886 | Surgery, orthopedics, cardiovascular intervention and specialty medical technologies | | Becton, Dickinson and Company (BD) | - | Franklin Lakes, United States | 1897 | Medication delivery, diagnostics, specimen management and interventional devices | | Stryker | - | Portage, United States | 1941 | Orthopedics, surgical equipment, neurotechnology and trauma devices | | B. Braun | - | Melsungen, Germany | 1839 | Infusion therapy, surgical products, dialysis and hospital care devices | The report provides detailed cross-comparison of key players across 4 performance parameters to identify competitive strengths and weaknesses. ### Top 4 Cross-Comparison KPIs * Installed Base Coverage * After-Sales Service Coverage * Oman Medical Device Revenue Growth * Gross Margin ### Analysis Covered * **Market Share Analysis:** Evaluates supplier positions across equipment, diagnostics, implants and consumables categories. * **Cross Comparison Matrix:** Benchmarks operational reach, service capability, growth and profitability indicators. * **SWOT Analysis:** Assesses technology strength, channel dependence, regulatory readiness and vulnerabilities. * **Pricing Strategy Analysis:** Compares tender pricing, bundled services, consumables economics and lifecycle contracts. * **Company Profiles:** Profiles Oman-relevant portfolios, operating footprints, positioning and strategic capabilities. --- --- ## Key Stakeholders # CHAPTER 10 - Key Target Audience Key stakeholders who can leverage from this market analysis for investment, strategy, and operational planning. * **Investors:** CAGR, installed base, recurring revenue, regulatory risk, margins * **Corporates:** tender pipeline, sourcing costs, service coverage, portfolio mix * **Government:** import dependence, hospital capacity, compliance, localization, resilience * **Operators:** uptime, procurement cycles, maintenance, connectivity, clinical utilization * **Financial institutions:** equipment finance, cash flow, receivables, project viability ### What You'll Gain * Market sizing and trajectory * Policy and compliance mapping * Trade exposure indicators * Segment structure and levers * Competitive landscape shortlist * CEO-grade risk priorities --- --- ## Research Methodology # CHAPTER 11 - Research Methodology ### Phase 1: Approach #### Desk Research * Medical device customs-flow analysis * Hospital capacity and procurement mapping * Device registration framework assessment * OEM portfolio and channel mapping #### Primary Research * Biomedical engineering director interviews * Hospital procurement manager interviews * Medical device country-manager interviews * Clinical laboratory director interviews #### Validation and Triangulation * 272-response primary sample validation * Customs-to-revenue reconciliation checks * Hospital installed-base cross validation * Device pricing benchmark normalization ### Phase 2: Market Size Estimation #### Top-Down Assessment * Healthcare expenditure and institutional procurement envelope * Allocation across hospitals, laboratories, clinics and homecare * Health infrastructure and customs statistics calibration #### Bottom-Up Modeling * OEM and distributor revenue universe estimates * Device ASP and lifecycle-service benchmarks * Installed units multiplied by annual economics #### Forecasting and Scenario Analysis * Hospital capacity, disease burden and technology mix * Registration, trade and procurement scenario drivers * Baseline, optimistic, and constrained projections through 2032 ### Phase 3: Primary Research Coverage #### Scope Item / Segments Coverage spans the Oman medical-device value chain from OEM supply and distribution through institutional procurement, diagnostics and clinical utilization. * Government Hospital Procurement * Private Hospitals & Specialty Clinics * Diagnostics & Laboratory Networks * OEMs, Distributors & Service Providers #### Sample Size A total of 272 respondents are structured across priority value-chain cohorts to support robust validation of the Oman Medical Devices Market. * Government Hospital Procurement - 78 respondents (Biomedical Engineering Director, Medical Procurement Manager) * Private Hospitals & Specialty Clinics - 72 respondents (Chief Operating Officer, Procurement Director) * Diagnostics & Laboratory Networks - 58 respondents (Laboratory Director, IVD Procurement Manager) * OEMs, Distributors & Service Providers - 64 respondents (Country Manager, Service Engineering Manager) #### Validation and Triangulation Validation reconciles respondent evidence across procurement, installed-base, distribution and end-use perspectives within the Oman medical-device value chain. * Cross-segment device-volume consistency testing * OEM-distributor-hospital revenue reconciliation * Operational-strategic respondent consistency checks * ASP and installed-base sanity testing --- ## Frequently Asked Questions # CHAPTER 12 - FAQs #### Q: How large is the Oman Medical Devices Market in 2025? **A:** The Oman Medical Devices Market is worth USD 566 million in 2025 under a domestic-consumption revenue lens covering regulated medical equipment, diagnostics, implants, monitoring systems and qualifying consumables. The estimate triangulates supplier revenue, relevant import categories, hospital procurement intensity and demand-side healthcare capacity. Import dependence remains high, making distributor margins, inventory and after-sales service material components of market economics. Hospital procurement continues to dominate high-value device demand, while laboratories and private providers contribute a growing recurring-revenue pool through diagnostics and consumable-linked platforms. **Data used:** USD 566 million market value (2025); 86% modeled device import dependence (2025) **So what:** Suppliers need an Oman-specific distribution and service model rather than relying on export-only account coverage. #### Q: What is the forecast for the Oman Medical Devices Market through 2032? **A:** The market is projected to reach USD 921 million by 2032, representing a 7.20% CAGR from the 2025 base. Growth is expected to be supported by hospital commissioning, equipment replacement, chronic-disease diagnostics, private-sector expansion and increasing adoption of connected technologies. Value growth should modestly exceed physical volume growth because digital imaging, minimally invasive platforms and connected monitoring carry higher technology and service content. The forecast assumes continued formalization of medical-device registration and no material disruption to Oman's import-dependent supply chain. **Data used:** USD 921 million projected value (2032); 7.20% CAGR (2025-2032) **So what:** The strongest investment cases should combine equipment placement with recurring service, software or consumables economics. #### Q: Where is the medical-device profit pool shifting in Oman? **A:** Profit pools are shifting toward recurring diagnostics, lifecycle services, connected equipment and procedure-linked consumables rather than relying solely on one-time capital equipment sales. Connected-device revenue is modeled to rise from 16% of device revenue in 2025 to 30% by 2032. Long-term technology partnerships provide evidence that hospitals increasingly value uptime, training, workflow integration and equipment lifecycle management. For OEMs, this changes commercial priorities from unit placement toward installed-base monetization, while distributors need stronger biomedical engineering and service capabilities. **Data used:** 16% connected-device revenue share (2025); 30% modeled share (2032) **So what:** Companies should prioritize recurring contracts, service attach rates and consumable pull-through alongside equipment sales. #### Q: What is the largest strategic risk in the Oman Medical Devices Market? **A:** Import dependence is the primary structural risk because most sophisticated medical equipment and many consumables are sourced internationally. HS 9018 medical instruments alone represented approximately USD 80.3 million of imports in 2024, excluding several other major device categories. Suppliers therefore face exposure to lead times, freight costs, foreign manufacturing capacity and local registration requirements. The growing regulatory linkage between establishment approval, product registration and clearance also raises the cost of weak local compliance, especially for companies pursuing public tenders or high-risk devices. **Data used:** USD 80.3 million HS 9018 imports (2024); 60-working-day device registration period **So what:** Inventory resilience and regulatory execution should be treated as competitive capabilities, not back-office functions. #### Q: How does Oman compare with other GCC medical-device markets? **A:** Oman is smaller than Saudi Arabia, UAE, Kuwait and Qatar in absolute market value, placing it fifth among the six GCC markets in the report's peer comparison. However, Oman's 7.20% forecast CAGR is stronger than the reported trajectories for Saudi Arabia and UAE, giving it an attractive growth-to-scale profile. The country's opportunity is therefore less about regional volume leadership and more about capturing hospital expansion, technology upgrades and import substitution opportunities with a relatively concentrated institutional buyer universe. **Data used:** Oman ranked 5th among six GCC peers (2025); 7.20% Oman CAGR (2025-2032) **So what:** Oman is best approached as a focused GCC growth market within a regional commercial platform. #### Q: Which demand factor has the greatest long-term impact on medical-device utilization in Oman? **A:** Chronic non-communicable disease is the most durable demand driver because it creates repeated diagnostic, monitoring and treatment-device utilization independent of individual hospital construction cycles. Oman records more than 6,500 new diabetes cases and more than 2,000 new cancer cases annually, while one in three individuals has high blood pressure. This supports glucose monitoring, laboratory diagnostics, imaging, cardiovascular devices, oncology workflows and home monitoring. The demand profile also encourages providers to invest in earlier diagnosis and higher-throughput clinical platforms. **Data used:** More than 6,500 new diabetes cases annually; more than 2,000 new cancer cases annually **So what:** Portfolios aligned with chronic-care pathways should generate more resilient recurring demand than episodic capital-equipment categories. #### Q: Which market-entry model is most suitable for medical-device companies entering Oman? **A:** A hybrid model combining OEM control with a qualified local distributor and technical-service capability is generally the most defensible approach. Device registration requires local establishment and manufacturer documentation, while institutional tenders require responsive logistics, clinical support and after-sales servicing. Direct strategic-account management is valuable for large imaging, laboratory and surgical platforms, but a local partner improves access to dispersed customers and government procurement processes. Companies should select partners based on regulatory capability, biomedical engineering coverage, working-capital strength and portfolio fit rather than sales reach alone. **Data used:** 60-working-day device registration period; 50 Ministry of Health hospitals at end-2023 **So what:** Distributor selection should be treated as a market-entry investment decision with explicit service and compliance KPIs. --- ## Table of Contents # Table of Contents ### Market Report Structure Comprehensive coverage across three strategic phases - Market Assessment, Go-To-Market Strategy, and Survey - delivering end-to-end insights from market analysis and execution roadmap to customer demand validation. ## Market Assessment Phase Supply-side and competitive intelligence covering market sizing, segmentation, competitive dynamics, regulatory landscape, and future forecasts. ### 1. Executive Summary and Approach ### 2. Oman Medical Devices Market Overview #### 2.1 Key Insights and Strategic Recommendations #### 2.2 Oman Medical Devices Market Overview #### 2.3 Definition and Scope #### 2.4 Evolution of Market Ecosystem #### 2.5 Timeline of Key Regulatory Milestones #### 2.6 Value Chain and Stakeholder Mapping #### 2.7 Business Cycle Analysis #### 2.8 Policy and Incentive Landscape ### 3. Oman Medical Devices Market Analysis #### 3.1 Growth Drivers ##### 3.1.1 Expansion of Hospital Infrastructure and Installed Clinical Capacity ##### 3.1.2 Rising Chronic Disease Diagnostic and Monitoring Intensity ##### 3.1.3 Private Healthcare Expansion and Quality Formalization ##### 3.1.4 Hospital and Private Capacity Expansion #### 3.2 Market Challenges ##### 3.2.1 High Dependence on Imported Devices and Components ##### 3.2.2 More Formal Regulatory and Market-Access Requirements ##### 3.2.3 Small National Scale and Concentrated High-Acuity Demand ##### 3.2.4 Distributor Working-Capital and Inventory Exposure #### 3.3 Market Opportunities ##### 3.3.1 CEPA-Enabled Sourcing and Supplier Portfolio Reconfiguration ##### 3.3.2 Connected Equipment and Lifecycle-Service Revenue ##### 3.3.3 Local Technical Service, Warehousing and Regulatory Support Hubs ##### 3.3.4 Chronic-Care Platform Expansion #### 3.4 Market Trends ##### 3.4.1 Shift Toward Connected Clinical Equipment ##### 3.4.2 Growth of Recurring Diagnostic Revenue ##### 3.4.3 Expansion of Minimally Invasive Platforms ##### 3.4.4 Increasing Lifecycle-Service Contracting #### 3.5 Government Regulation ##### 3.5.1 Medical Device Product Registration ##### 3.5.2 Medical Device Manufacturer Registration ##### 3.5.3 High-Risk Device Regulatory Oversight ##### 3.5.4 Establishment Approval and Clearance Linkage ### 4. SWOT Analysis ### 5. Stakeholder Analysis ### 6. Porter's Five Forces Analysis ### 7. Oman Medical Devices Market Size, 2020-2025 #### 7.1 By Value #### 7.2 By Volume #### 7.3 By Average Selling Price ### 8. Oman Medical Devices Market Segmentation #### 8.1 Product Type ##### 8.1.1 Diagnostic Imaging ##### 8.1.2 In Vitro Diagnostics ##### 8.1.3 Cardiovascular Devices ##### 8.1.4 Orthopedic & Implantable Devices ##### 8.1.5 General & Surgical Devices #### 8.2 Care Setting ##### 8.2.1 Public Hospitals ##### 8.2.2 Private Hospitals ##### 8.2.3 Specialty Clinics ##### 8.2.4 Diagnostic Laboratories ##### 8.2.5 Home Healthcare #### 8.3 End User ##### 8.3.1 Ministry of Health Providers ##### 8.3.2 Other Government Providers ##### 8.3.3 Private Hospital Groups ##### 8.3.4 Diagnostic Networks ##### 8.3.5 Individual Patients #### 8.4 Disease Area ##### 8.4.1 Cardiovascular & Stroke ##### 8.4.2 Diabetes & Metabolic ##### 8.4.3 Oncology ##### 8.4.4 Orthopedics & Trauma ##### 8.4.5 Renal & Critical Care #### 8.5 Channel ##### 8.5.1 Public Tenders ##### 8.5.2 Direct Institutional Sales ##### 8.5.3 Authorized Distributors ##### 8.5.4 Private Group Procurement ##### 8.5.5 Retail & E-Commerce #### 8.6 Technology ##### 8.6.1 Conventional Electromechanical ##### 8.6.2 Digital & Connected Devices ##### 8.6.3 AI-Enabled Diagnostics ##### 8.6.4 Minimally Invasive Platforms ##### 8.6.5 Point-of-Care Devices #### 8.7 Geography ##### 8.7.1 Muscat Governorate ##### 8.7.2 Al Batinah North & South ##### 8.7.3 Dhofar Governorate ##### 8.7.4 Interior, Sharqiyah & Border Governorates ### 9. Oman Medical Devices Market Competitive Analysis #### 9.1 Market Share of Key Players (Micro, Small, Medium, Large Enterprises) #### 9.2 Cross Comparison of Key Players ##### 9.2.1 Company Name ##### 9.2.2 Group Size (Large, Medium, or Small as per industry convention) ##### 9.2.3 Installed Base Coverage ##### 9.2.4 After-Sales Service Coverage ##### 9.2.5 Oman Medical Device Revenue Growth ##### 9.2.6 Gross Margin #### 9.3 SWOT Analysis of Top Players #### 9.4 Pricing Analysis #### 9.5 Detailed Profile of Major Companies ##### 9.5.1 Siemens Healthineers ##### 9.5.2 GE HealthCare ##### 9.5.3 Philips ##### 9.5.4 Roche Diagnostics ##### 9.5.5 Abbott ##### 9.5.6 Medtronic ##### 9.5.7 Johnson & Johnson MedTech ##### 9.5.8 Becton, Dickinson and Company (BD) ##### 9.5.9 Stryker ##### 9.5.10 B. Braun ### 10. Oman Medical Devices Market End-User Analysis #### 10.1 Procurement Behavior of Key End-Users ##### 10.1.1 Ministry of Health Tender Procurement ##### 10.1.2 Private Hospital Direct Procurement ##### 10.1.3 Laboratory Platform Procurement ##### 10.1.4 Specialty Clinic Device Procurement #### 10.2 Corporate Spend Patterns ##### 10.2.1 Capital Equipment Budget Cycles ##### 10.2.2 Consumables and Reagent Spend ##### 10.2.3 Maintenance Contract Spend ##### 10.2.4 Technology Upgrade Expenditure #### 10.3 Pain Point Analysis by End-User Category ##### 10.3.1 Equipment Lead-Time Risk ##### 10.3.2 Biomedical Service Availability ##### 10.3.3 Consumable Supply Continuity ##### 10.3.4 System Interoperability Constraints #### 10.4 User Readiness for Adoption ##### 10.4.1 Connected Monitoring Readiness ##### 10.4.2 AI Diagnostics Readiness ##### 10.4.3 Point-of-Care Adoption Readiness ##### 10.4.4 Minimally Invasive Technology Readiness #### 10.5 Post-Deployment ROI and Use Case Expansion ##### 10.5.1 Equipment Utilization Improvement ##### 10.5.2 Reduced Clinical Workflow Time ##### 10.5.3 Predictive Maintenance Economics ##### 10.5.4 Recurring Consumables Pull-Through ### 11. Oman Medical Devices Market Future Size, 2025-2032 #### 11.1 By Value #### 11.2 By Volume #### 11.3 By Average Selling Price ## Go-To-Market Strategy Phase Entry strategy evaluation, execution roadmap, partner recommendations, and profitability outlook. ### 1. Whitespace Analysis and Business Model Canvas #### 1.1 Connected Diagnostic Platforms #### 1.2 Biomedical Lifecycle Services #### 1.3 Point-of-Care Diagnostics #### 1.4 Regional Inventory Hubs ### 2. Marketing and Positioning Recommendations #### 2.1 Clinical Outcome Positioning #### 2.2 Total Cost of Ownership Messaging #### 2.3 Regulatory Compliance Positioning #### 2.4 Lifecycle Service Differentiation ### 3. Distribution Plan #### 3.1 Muscat Direct-Key-Account Coverage #### 3.2 Governorate Distributor Coverage #### 3.3 Biomedical Service Network #### 3.4 Regional Safety-Stock Deployment ### 4. Channel and Pricing Gaps #### 4.1 Public Tender Pricing Gaps #### 4.2 Private Hospital Bundle Pricing #### 4.3 Service Contract Attach Rates #### 4.4 Consumables Pull-Through Pricing ### 5. Unmet Demand and Latent Needs #### 5.1 Faster Regional Service Response #### 5.2 Connected Asset Management #### 5.3 Point-of-Care Diagnostic Access #### 5.4 Local Inventory Availability ### 6. Customer Relationship #### 6.1 Key Account Governance #### 6.2 Clinical Training Programs #### 6.3 Preventive Maintenance Engagement #### 6.4 Procurement Renewal Management ### 7. Value Proposition #### 7.1 Clinical Reliability #### 7.2 Lower Lifecycle Cost #### 7.3 Regulatory Readiness #### 7.4 Faster Technical Support ### 8. Key Activities #### 8.1 Device Registration #### 8.2 Distributor Qualification #### 8.3 Tender Pipeline Development #### 8.4 Installed-Base Service Expansion ### 9. Entry Strategy Evaluation #### 9.1 Domestic Market Entry Strategy ##### 9.1.1 Regulatory Establishment Setup ##### 9.1.2 Qualified Distributor Appointment ##### 9.1.3 Priority Hospital Account Mapping ##### 9.1.4 Biomedical Service Deployment #### 9.2 Export Entry Strategy ##### 9.2.1 India-Oman CEPA Sourcing ##### 9.2.2 GCC Re-Export Assessment ##### 9.2.3 Port and Warehouse Selection ##### 9.2.4 Regional Distributor Governance ### 10. Entry Mode Assessment #### 10.1 Local Distributor Model #### 10.2 Direct Subsidiary Model #### 10.3 Hybrid Key-Account Model #### 10.4 Service Joint-Venture Model ### 11. Capital and Timeline Estimation #### 11.1 Regulatory Setup Capital #### 11.2 Inventory Working Capital #### 11.3 Service Infrastructure Capital #### 11.4 Commercial Ramp Timeline ### 12. Control vs Risk Trade-Off #### 12.1 Distributor Control #### 12.2 Regulatory Liability #### 12.3 Inventory Exposure #### 12.4 Receivables Risk ### 13. Profitability Outlook #### 13.1 Equipment Gross Margin #### 13.2 Service Contract Margin #### 13.3 Consumables Recurring Margin #### 13.4 Working-Capital Return ### 14. Potential Partner List #### 14.1 Authorized Medical Device Distributors #### 14.2 Biomedical Engineering Service Providers #### 14.3 Hospital Technology Partners #### 14.4 Logistics and Warehousing Providers ### 15. Execution Roadmap #### 15.1 Phased Plan for Market Entry ##### 15.1.1 Market Setup ##### 15.1.2 Market Entry ##### 15.1.3 Growth Acceleration ##### 15.1.4 Scale and Stabilize #### 15.2 Key Activities and Milestones ##### 15.2.1 Complete Device Registration ##### 15.2.2 Secure Priority Distribution Coverage ##### 15.2.3 Win Anchor Hospital Accounts ##### 15.2.4 Expand Recurring Service Revenue ## Survey Phase Demand-side primary research conducted through structured interviews and online surveys with end users across priority metros and Tier 2/3 cities to capture consumption behavior, unmet needs, and purchase drivers. ### 1. Research Design and Sample Architecture #### 1.1 Research Objectives and Scope #### 1.2 Sample Size Rationale and Representation #### 1.3 Customer Cohort Definitions #### 1.4 Geographic Coverage - Priority Metros and Tier 2/3 Cities ### 2. Data Collection Methodology #### 2.1 Structured Interview Framework (50 In-Depth Interviews) ##### 2.1.1 Interview Guide and Question Design ##### 2.1.2 Respondent Recruitment and Screening Criteria ##### 2.1.3 Interview Execution and Quality Control ##### 2.1.4 Qualitative Coding and Insight Extraction #### 2.2 Online Survey Design (200 Structured Surveys) ##### 2.2.1 Survey Instrument and Attribute Coverage ##### 2.2.2 Platform Selection and Distribution Channels ##### 2.2.3 Response Validation and Data Cleaning ##### 2.2.4 Statistical Significance and Margin of Error ### 3. Customer Cohort Profiles #### 3.1 Cohort 1 - Large Enterprise End Users ##### 3.1.1 Cohort Definition and Size ##### 3.1.2 Key Demand Attributes ##### 3.1.3 Purchase Decision Drivers ##### 3.1.4 Represented Sample Size and Metro Distribution #### 3.2 Cohort 2 - Mid-Size Enterprise End Users ##### 3.2.1 Cohort Definition and Size ##### 3.2.2 Key Demand Attributes ##### 3.2.3 Purchase Decision Drivers ##### 3.2.4 Represented Sample Size and City Distribution #### 3.3 Cohort 3 - Small and Emerging Enterprise End Users ##### 3.3.1 Cohort Definition and Size ##### 3.3.2 Key Demand Attributes ##### 3.3.3 Purchase Decision Drivers ##### 3.3.4 Represented Sample Size and Tier 2/3 City Distribution #### 3.4 Cohort 4 - Institutional and Government End Users ##### 3.4.1 Cohort Definition and Size ##### 3.4.2 Key Demand Attributes ##### 3.4.3 Procurement and Compliance Drivers ##### 3.4.4 Represented Sample Size and Regional Distribution ### 4. Demand Attributes Analysis #### 4.1 Macroeconomic and Sectoral Growth Influences on Demand ##### 4.1.1 GDP and Healthcare Investment Linkages ##### 4.1.2 Hospital Infrastructure Expansion Impact ##### 4.1.3 Capital Investment Cycles and Procurement Timing ##### 4.1.4 Import Dependency on Oman Medical Devices Market #### 4.2 End-User Behavior and Consumption Patterns ##### 4.2.1 Frequency and Volume of Purchases ##### 4.2.2 Replacement and Procurement Cycle Variations ##### 4.2.3 Brand Loyalty vs. Price Sensitivity Trade-Off ##### 4.2.4 Switching Triggers and Retention Factors #### 4.3 Pricing Perception and Value Assessment ##### 4.3.1 Willingness to Pay Across Cohorts ##### 4.3.2 Price Benchmarking Against Alternative Platforms ##### 4.3.3 Regional Pricing Disparities ##### 4.3.4 Total Cost of Ownership Perception #### 4.4 Quality, Safety, and Compliance Expectations ##### 4.4.1 Quality Standards and Certification Requirements ##### 4.4.2 Safety and Regulatory Compliance Awareness ##### 4.4.3 Perception of Domestic vs. Imported Offerings ##### 4.4.4 After-Sales Service and Support Expectations #### 4.5 Cultural, Regional, and Contextual Demand Factors ##### 4.5.1 Regional Healthcare Clusters and Demand Hotspots ##### 4.5.2 Operational Norms Influencing Procurement ##### 4.5.3 Clinical Peer Influence and Institutional Impact ##### 4.5.4 Digital Adoption and E-Procurement Readiness #### 4.6 Marketing, Awareness, and Channel Influence ##### 4.6.1 Impact of Medical Conferences and Industry Events ##### 4.6.2 Role of Digital Marketing and Clinical Education ##### 4.6.3 Distributor Influence on Device Purchase ##### 4.6.4 OEM and Clinical Partner Impact ### 5. Unmet Needs and Latent Demand Signals #### 5.1 Identified Gaps Between Current Supply and User Expectations #### 5.2 Latent Demand in Underpenetrated Segments #### 5.3 Willingness to Adopt New Formats or Technologies #### 5.4 Pain Points Surfaced Across Cohorts ### 6. Key Findings and Strategic Implications #### 6.1 Top Demand Drivers Ranked by Cohort #### 6.2 Barriers to Purchase and Adoption #### 6.3 High-Priority Customer Segments for Market Entry #### 6.4 Recommendations for Product, Pricing, and Channel Strategy ### Disclaimer ### Contact Us